209 related articles for article (PubMed ID: 32623821)
21. Comparison of the UCLA Integrated Staging System and the Leibovich score in survival prediction for patients with nonmetastatic clear cell renal cell carcinoma.
Tan MH; Kanesvaran R; Li H; Tan HL; Tan PH; Wong CF; Chia KS; Teh BT; Yuen J; Chong TW
Urology; 2010 Jun; 75(6):1365-1370; 1370.e1-3. PubMed ID: 20022084
[TBL] [Abstract][Full Text] [Related]
22. External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
Marconi L; de Bruijn R; van Werkhoven E; Beisland C; Fife K; Heidenreich A; Kapoor A; Karam J; Kauffmann C; Klatte T; Ljungberg B; Matin S; Sjoberg D; Staehler M; Stewart GD; Tanguay S; Uzzo R; Welsh S; Wood L; Wood C; Bex A
World J Urol; 2018 Dec; 36(12):1973-1980. PubMed ID: 30069581
[TBL] [Abstract][Full Text] [Related]
23. A CT-based deep learning radiomics nomogram outperforms the existing prognostic models for outcome prediction in clear cell renal cell carcinoma: a multicenter study.
Nie P; Yang G; Wang Y; Xu Y; Yan L; Zhang M; Zhao L; Wang N; Zhao X; Li X; Cheng N; Wang Y; Chen C; Wang N; Duan S; Wang X; Wang Z
Eur Radiol; 2023 Dec; 33(12):8858-8868. PubMed ID: 37389608
[TBL] [Abstract][Full Text] [Related]
24. External validation of the REMARCC model for the selection of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma: A multicenter retrospective study.
Okita K; Hatakeyama S; Naito S; Numakura K; Kato R; Koguchi T; Kojima T; Kawasaki Y; Kandori S; Kawamura S; Nishiyama H; Ito A; Kojima Y; Habuchi T; Obara W; Tsuchiya N; Ohyama C
Urol Oncol; 2021 Dec; 39(12):836.e11-836.e17. PubMed ID: 34544649
[TBL] [Abstract][Full Text] [Related]
25. Baseline tumor volume in assessing prognosis of patients with intermediate-risk synchronous metastatic renal cell carcinoma.
de Bruijn RE; Nijkamp J; Noe A; Horenblas S; Haanen JB; Prevoo W; Bex A
Urol Oncol; 2016 Jun; 34(6):258.e7-258.e13. PubMed ID: 26822077
[TBL] [Abstract][Full Text] [Related]
26. Morphomics Can Predict Oncological Features and Survival of Metastatic Renal Cell Carcinoma After Cytoreductive Nephrectomy.
Shao IH; Chang YH; Sheng TW; Tan CC; Wang LJ; Chuang CK; Wu CT; Pang ST
Anticancer Res; 2021 Oct; 41(10):5203-5211. PubMed ID: 34593473
[TBL] [Abstract][Full Text] [Related]
27. Prognostic model of upfront cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors and/or targeted agents.
Teishima J; Goto K; Sekino Y; Mita K; Hayashi T; Hasegawa Y; Kato M; Kajiwara M; Shigeta M; Maruyama S; Kadonishi Y; Fujiwara S; Kobayashi K; Asano K; Hinata N
Int Urol Nephrol; 2022 Jun; 54(6):1225-1232. PubMed ID: 35314918
[TBL] [Abstract][Full Text] [Related]
28. Cytoreductive nephrectomy in metastatic renal cell carcinoma: outcome of patients treated with a multidisciplinary, algorithm-driven approach.
Liu WK; Lam JM; Butters T; Grant M; Jackson-Spence F; Bex A; Powles T; Szabados B
World J Urol; 2020 Dec; 38(12):3199-3205. PubMed ID: 32128610
[TBL] [Abstract][Full Text] [Related]
29. Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma.
Silagy AW; Kotecha RR; Weng S; Holmes A; Singla N; Mano R; Attalla K; Weiss KL; DiNatale RG; Patil S; Coleman JA; Motzer RJ; Russo P; Voss MH; Hakimi AA
Cancer; 2021 Nov; 127(21):3946-3956. PubMed ID: 34286865
[TBL] [Abstract][Full Text] [Related]
30. Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma.
Day D; Kanjanapan Y; Kwan E; Yip D; Lawrentschuk N; Davis ID; Azad AA; Wong S; Rosenthal M; Gibbs P; Tran B
Intern Med J; 2016 Nov; 46(11):1291-1297. PubMed ID: 27507629
[TBL] [Abstract][Full Text] [Related]
31. Metastatic Tumor Burden Does Not Predict Overall Survival Following Cytoreductive Nephrectomy for Renal Cell Carcinoma: a Novel 3-Dimensional Volumetric Analysis.
Blute ML; Ziemlewicz TJ; Lang JM; Kyriakopoulos C; Jarrard DF; Downs TM; Grimes M; Shi F; Mann MA; Abel EJ
Urology; 2017 Feb; 100():139-144. PubMed ID: 27667156
[TBL] [Abstract][Full Text] [Related]
32. Hospital volume and short-term outcomes after cytoreductive nephrectomy.
Xia L; Strother MC; Taylor BL; Chelluri RR; Pulido JE; Guzzo TJ
J Surg Oncol; 2018 Jun; 117(7):1589-1596. PubMed ID: 29575038
[TBL] [Abstract][Full Text] [Related]
33. Comparison of pre-treatment MSKCC and IMDC prognostic risk models in patients with synchronous metastatic renal cell carcinoma treated in the era of targeted therapy.
Noe A; de Bruijn RE; Blank C; Horenblas S; Haanen J; Bex A
World J Urol; 2016 Aug; 34(8):1067-72. PubMed ID: 26832350
[TBL] [Abstract][Full Text] [Related]
34. Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era - a multi-institutional retrospective study.
Kato R; Naito S; Numakura K; Hatakeyama S; Koguchi T; Kojima T; Kawasaki Y; Kandori S; Kawamura S; Arai Y; Ito A; Nishiyama H; Kojima Y; Ohyama C; Habuchi T; Tsuchiya N; Obara W
Int J Clin Oncol; 2022 Mar; 27(3):563-573. PubMed ID: 34973106
[TBL] [Abstract][Full Text] [Related]
35. Integrated staging systems for conventional renal cell carcinoma: a comparison of two prognostic models.
Martella O; Galatioto GP; Necozione S; Pomante R; Vicentini C
Arch Ital Urol Androl; 2011 Sep; 83(3):121-7. PubMed ID: 22184835
[TBL] [Abstract][Full Text] [Related]
36. Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Graham J; Wells JC; Donskov F; Lee JL; Fraccon A; Pasini F; Porta C; Bowman IA; Bjarnason GA; Ernst DS; Rha SY; Beuselinck B; Hansen A; North SA; Kollmannsberger CK; Wood LA; Vaishampayan UN; Pal SK; Choueiri TK; Heng DYC
Eur Urol Oncol; 2019 Nov; 2(6):643-648. PubMed ID: 31411994
[TBL] [Abstract][Full Text] [Related]
37. Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data.
de Bruijn R; Wimalasingham A; Szabados B; Stewart GD; Welsh SJ; Kuusk T; Blank C; Haanen J; Klatte T; Staehler M; Powles T; Bex A
Eur Urol Oncol; 2020 Apr; 3(2):168-173. PubMed ID: 31956080
[TBL] [Abstract][Full Text] [Related]
38. Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
Margulis V; Shariat SF; Rapoport Y; Rink M; Sjoberg DD; Tannir NM; Abel EJ; Culp SH; Tamboli P; Wood CG
Eur Urol; 2013 May; 63(5):947-52. PubMed ID: 23273681
[TBL] [Abstract][Full Text] [Related]
39. Survival advantage of upfront cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma compared with systemic and palliative treatments in a real-world setting.
Ljungberg B; Sundqvist P; Lindblad P; Kjellman A; Thorstenson A; Hellström M; Kröger Dahlin BI; Thomasson M; Harmenberg U; Lundstam S
Scand J Urol; 2020 Dec; 54(6):487-492. PubMed ID: 32897123
[TBL] [Abstract][Full Text] [Related]
40. Lymph node dissection during cytoreductive nephrectomy: a retrospective analysis.
Feuerstein MA; Kent M; Bernstein M; Russo P
Int J Urol; 2014 Sep; 21(9):874-9. PubMed ID: 24712686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
